Epicrispr Biotechnologies
PrivateLast Round
Series C
Aug 11, 2026
Est. Valuation
$95.14M
Total Funding Raised
$213M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Epicrispr Biotechnologies is a biotechnology company developing gene-modulating therapies using its proprietary Gene Expression Modulation System (GEMS) to treat a range of genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epicrispr Biotechnologies Comparables
Compare Epicrispr Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tune Therapeutics | 84% | |
| Moonwalk Biosciences | 84% | |
| Chroma Medicine | 83% |
Epicrispr Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 11, 2026 | ||||
| Series B | Mar 26, 2025 | ||||
| Series A | Jul 12, 2022 |
Epicrispr Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| Horizons Ventures | Series A |
| abrdn Inc. | Series C |
| Ally Bridge Group | Series B |
| Readout Capital | Series C |
| Cormorant Asset Management | Series C |
| Duquesne Family Office | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
Grew 18% QoQ, from 44 to 52 employees.
- Aug 11, 2026
$90M round led by Janus Henderson Group and Octagon Capital Advisors.
Recent news
Latest coverage and updates
- is_developingAug 11, 2026
Epicrispr Biotechnologies, Inc. is developing epigenetic medicine for facioscapulohumeral muscular dystrophy on Apr 1st '26.
- receives_financingAug 11, 2026
Epicrispr Biotechnologies, Inc. received financing of $90M in Series C on Aug 1st '26.
- hiresAug 11, 2026
Epicrispr Biotechnologies, Inc. hires Anran Li as board.
- is_developingJul 8, 2026
Epicrispr Biotechnologies, Inc. is developing EPI-321 on Jul 13th '26.
Epicrispr Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Epicrispr Biotechnologies's valuation, stock price, and market status.
Is Epicrispr Bio a public or private company?
Epicrispr Bio is a private company.
What is the current stock price of Epicrispr Bio?
Epicrispr Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Epicrispr Bio worth (valuation)?
Epicrispr Bio's valuation is estimated at $95.1M based on funding round data.
Can I buy Epicrispr Bio stock?
Epicrispr Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Epicrispr Bio's last funding round?
Epicrispr Bio's most recent funding round was Series B on July 12, 2022.
Who are the main investors in Epicrispr Bio?
Key investors in Epicrispr Bio include Horizons Ventures, Ally Bridge Group.
Will Epicrispr Bio IPO soon?
No public IPO plans have been announced for Epicrispr Bio.
How can I track Epicrispr Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Epicrispr Bio's secondary market activity and sign up for updates.